Evotec SE Sponsored ADR
(NASDAQ: EVO)
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
4.260
+0.210
(+5.19%)
Range
4.170 - 4.265
(2.28%)
Open
4.200
Previous Close
4.050
Bid Price
10.800
Bid Volume
11
Ask Price
11.300
Ask Volume
8
Volume
86,945
Value
-
Remark
View All Events
No Post Available
Please login to view stock data and analysis